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Abstract Background: There are few centres which spe-
cialise in the care of adults with inborn errors of metabo-
lism (IEM). To anticipate facilities and staffing needed at
these centres, it is of interest to know the distribution of the
different disorders.
Methods: A survey was distributed through the list-serve
of the SSIEM Adult Metabolic Physicians group asking
clinicians for number of patients with confirmed diagnoses,
types of diagnoses and age at diagnosis.
Results: Twenty-four adult centres responded to our
survey with information on 6,692 patients. Of those 6,692
patients, 510 were excluded for diagnoses not within the
IEM spectrum (e.g. bone dysplasias, hemochromatosis) or
for age less than 16 years, leaving 6,182 patients for final
analysis. The most common diseases followed by the adult
centres were phenylketonuria (20.6%), mitochondrial dis-
orders (14%) and lysosomal storage disorders (Fabry
disease (8.8%), Gaucher disease (4.2%)). Amongst the
disorders that can present with acute metabolic decompen-
sation, the urea cycle disorders, specifically ornithine
transcarbamylase deficiency, were most common (2.2%),
followed by glycogen storage disease type I (1.5%) and
maple syrup urine disease (1.1%). Patients were frequently
diagnosed as adults, particularly those with mitochondrial
disease and lysosomal storage disorders.
Conclusions: A wide spectrum of IEM are followed at
adult centres. Specific knowledge of these disorders is
needed to provide optimal care including up-to-date
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CESD Cholesteryl ester storage disease
CPEO Chronic progressive external ophthalmoplegia
CPT1 Carnitine palmitoyltransferase 1
CPT2 Carnitine palmitoyltransferase 2
GSDb Glycogen storage disease
IEM Inborn errors of metabolism
LCHAD Long-chain 3-hydroxyacyl-CoA dehydrogenase
deficiency
MCAD Medium-chain acyl-CoA dehydrogenase defi-
ciency
MELAS Mitochondrial myopathy, encephalitis, lactic
acidosis and stroke-like episodes
MERRF Myoclonic epilepsy with ragged red fibres
MIDD Maternally inherited diabetes and deafness
MMA Methylmalonic aciduria
MPS Mucopolysaccharidosis
MSUD Maple syrup urine disease
MTHFR Methylenetetrahydrofolate reductase deficiency
MTP Mitochondrial trifunctional protein deficiency
NAGS N-Acetyl glutamate synthase deficiency
OTC Ornithine transcarbamylase deficiency
PKU Phenylketonuria
SCAD Short-chain acyl-CoA dehydrogenase deficiency
SSIEM Society for the Study of Inborn Errors of
Metabolism
TMAU Trimethylaminuria




The care of adults with inborn errors of metabolism (IEM) is
an expanding subspecialty due to the improved survival of
children with classical IEM, the recognition of milder forms
of disease diagnosed in adulthood and late-onset disorders
presenting in adulthood. Reflecting this increased interest,
the Adult Metabolic Physicians working group of the Society
for the Study of Inborn Errors of Metabolism (SSIEM)
was formed in 2010 under the leadership of Frederic Sedel
(Pitié-Salpêtrière Hospital, Paris, France) (http://www.ssiem.
org/amp/welcome.asp). Clinical departments with a particu-
lar adult interest have developed in various countries,
including large and well-established centres in the United
Kingdom, Canada and the Netherlands and national net-
works such as in France the SFEIM-A – Société Française
des Erreurs Innées du Métabolisme Adulte.
The prevalence of IEM in the adult population is
unknown, as are the number and types of these patients
being seen by metabolic physicians. How many of these
patients were diagnosed and managed in childhood, as
opposed to presenting with an adult-age diagnosis, is also
unknown. Further information regarding the care of this
patient population would thus be useful to anticipate needs
for adult services, provide rationale for development of
protocols and education, serve as a background for aware-
ness amongst other physicians and identify centres with
specific expertise for consultation, research and training.
Methods
All physicians who participate in the SSIEM Adult Meta-
bolic Physicians group were contacted through e-mail in
2011 to submit anonymised patient data including diagnosis,
age group at diagnosis (unknown, newborn screen, neonatal
(week 1 of life), infantile (0–2 years), childhood (3–10
years), juvenile (11–16 years), adult (>16 years)) and
current age. Initial data included all patients seen at each
centre; hence, a number of patients with diagnoses not
traditionally categorised as IEM were submitted but subse-
quently excluded from the analysis (excluded diagnoses list
available from authors on request). Patients submitted who
were younger than 16 years were also excluded. Only
patients with a biochemical or genetically confirmed diagno-
sis were included in the analysis.
The numbers of each disorder were counted and grouped
into metabolic subtypes. The median current age and age
group at diagnosis for each disorder were calculated.
Updated total patient numbers were requested in 2014 to
assess growth in service demand over this time. A number
of French centres submitted initial limited data sets at this
time which included patient numbers and diagnoses at each
centre, but without current patient age or age at diagnosis.
Results
Initially 15 centres responded to our survey with data on
4,998 patients. With the addition of data from the French
centres that are organised through a dedicated national
society (the SFEIM-A, 1,694 patients), data was available
on a total of 6,692 patients (Supplementary Table S1). Five
hundred and ten patients were excluded from analysis for
diagnoses not within the IEM spectrum (e.g. bone dyspla-
sias, haemochromatosis) or for age less than 16 years
(Supplementary Table S2), leaving 6,182 patients for final
analysis. Two hundred and thirty-six separate diagnoses
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were documented, although in some disorders there was the
potential for diagnostic overlap or ambiguity; for example,
12 patients were labelled with hyperhomocystinaemia, 244
were labelled with homocystinuria and a single patient was
labelled as homocystinuria and MTHFR deficiency. The
number of patients submitted from each centre varied from
7 to 1,418 (Table 1).
As expected, the most frequent disorder was phenylke-
tonuria (PKU), representing 1,274 (20.6%) cases. The
median age of PKU patients was 34 years, and diagnosis
was predominantly via a newborn screening programme
(413 of 499 (82.8%) patients with age of diagnosis data).
Forty-six PKU patients were diagnosed as juveniles (13)
or adults (33). The next most common diagnosis was
Fabry disease (544 patients, 8.8%), followed by CPEO
(263 patients, 4.3%) and Gaucher disease (261 patients,
4.2%). The 30 most common diagnoses are listed in
Table 2.
Table 1 Submitted patient numbers from each clinical centre. Patients
in the 2011 column were included in age and age at diagnosis
analysis. Patients in the 2014 column were included in total patient



























Hamburg, Germany 132 155
Lille, France 124 126
Udine, Italy 117 (submitted
in 2013)
117




Doha, Qatar 71 95
Grenoble, France 35 43

















Table 2 Thirty most frequent diagnoses and ages, including French
patients added in 2014 in the total number, but not in the analysis of
median age and age range which were not available for French
patients. Four thousand eight hundred and seventy-one patients are








PKU 1,274 34 16–83 20.6
Fabry 544 45 19–82 8.8
Mitochondrial –
CPEO
263 59.5 18–85 4.3
Gaucher 261 48 17–90 4.2
Mitochondrial 253 49 19–84 4.1
Homocystinuria 244 35 16–84 3.9
X-ALD 237 47 16–82 3.8
GSD II 220 55 18–83 3.6
Galactosaemia 165 29 18–64 2.7
Mitochondrial –
MELAS
159 42 19–71 2.6
TMAU 146 44 20–79 2.4
GSD V 145 51.5 20–80 2.3
OTC 136 33 20–79 2.2
Hypophosphataemic
rickets
87 36 18–79 1.4
MSUD 69 27 16–52 1.1
GSD III 60 38 21–67 1.0
GSD Ia 59 29 20–59 1.0
Niemann-Pick C 56 35 18–59 0.9
Mitochondrial –
POLG
50 50 20–67 0.8
MCAD 48 23 18–49 0.8
MMA 48 25 19–44 0.8
Niemann-Pick B 45 39 0–60 0.7
MPS I 45 33.5 18–59 0.7
CPT2 deficiency 43 36 20–77 0.7
Carnitine transporter
deficiency
40 31 17–61 0.6
Mitochondrial –
MERRF
36 42 22–66 0.6
Porphyria 36 53 18–82 0.6
Porphyria – acute
intermittent
35 51 25–81 0.6
MPS IV 35 35 19–59 0.6
Alkaptonuria 32 52 20–86 0.5
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Disorders of amino acid metabolism (2,061 patients)
were the most frequent when data were analysed according
to types of disease (Table 3). Lysosomal storage disorders
were the next most prevalent (1,220 patients) and were
predominately Fabry (544), Gaucher (261) and Pompe
(220) diseases. The broad group of mitochondrial disorders
was strongly represented with 867 patients. Within these
867 patients, 253 did not have their phenotype described
further, 162 had MELAS, 263 had CPEO, 23 had MIDD,
19 had Kearns-Sayre and other mitochondrial phenotypes
were present to lesser degrees. The age group at onset was
documented for 377 of these mitochondrial patients, and of
these 317 were diagnosed in adulthood. Out of 258 patients
with peroxisomal disorders, 237 had X-ALD. Patient
numbers for each condition within the urea cycle disorders
(201), disorders of fatty acid oxidation (225), mucopoly-
saccharidoses (141) and glycogen storage diseases (370,
excluding Pompe) are shown in Table 4.
Data for the age group at diagnosis was available for
2,022 patients, all of whom were submitted in the initial
group of cases (Table 5). Many were diagnosed as adults
(925 patients, 45.7%), with the known remainder predomi-
nantly diagnosed via newborn screening (455 patients,
22.5%), although this number is largely patients with PKU
(413 patients). Mitochondrial diseases accounted for the
largest number of adult diagnoses (317 patients) followed
by Fabry disease (137 patients) and then homocystinuria
(45 patients).
Of the conditions that may present with fatal decom-
pensations at any time of life, 29 patients with OTC
deficiency were diagnosed as adults (age at diagnosis was
available for 46 patients); however, patient gender was not
Table 3 Number of patients grouped by disease categories, as defined
in Saudubray et al. (2012). The urea cycle disorders are counted
amongst the aminoacidopathies. The patient numbers for the
l y s o s om a l s t o r a g e d i s o r d e r s d o n o t i n c l u d e t h e
mucopolysaccharidoses or peroxisomal disorders as they are counted








Fatty acid oxidation 221
Mucopolysaccharidoses 141
Porphyrias 101
Vitamin and cofactor 93
Table 4 Patient numbers for each diagnosis in the urea cycle
disorders, fatty acid oxidation disorders, mucopolysaccharidoses,
glycogen storage diseases (excluding GSD II) and total lysosomal
disorders. Some disorders are divided into separate categories,
depending on the amount of diagnostic detail submitted by the
clinician; e.g. 11 patients with citrullinaemia may be type I or type II,
but were not specified in the data submitted. Patient numbers include
the French data from 2014












































requested and so the proportion of these that are female is
not known. Where age at diagnosis was submitted, all of
the acute porphyrias were diagnosed in adulthood. Others
with potentially unstable conditions were generally diag-
nosed in infancy or early childhood, although five patients
with MSUD and two patients with MMAwere diagnosed as
juveniles.
Conditions where some form of treatment is available,
whether dietary, enzyme replacement or other pharmaco-
logical means, were represented by 4,649 (75%) patients
(Supplementary Table S3). Disorders in which bone
marrow transplant may be offered, such as metachromatic
leukodystrophy, were not included in this “treatable”
cohort, although we appreciate that an argument could be
made to include them.
Discussion
This paper is the first analysis of patient data from a group
of clinical centres with a dedicated interest in adult patients
with IEM. It demonstrates the wide spectrum of disease
seen and is striking for the large numbers of patients that
were diagnosed as adults and the growth in demand for
these services in a relatively short period of time. We
recognise that this data set is limited due to its ascertain-
ment biases and as such does not represent a true picture of
the burden of IEM in adults; however, it does make
apparent that IEM in adults is far from restricted to PKU,
mitochondrial disease and the lysosomal disorders.
Disease Frequencies
Newborn screening for PKU was instituted in many
countries in the late 1960s and early 1970s, and this in
combination with its relatively high prevalence (1 in 10,000
in Australia) makes it unsurprising that it is the most
common disorder in this cohort. All centres saw patients
with PKU, although the proportion varied widely. The
frequency of mitochondrial patients is perhaps lower than
expected as various studies have indicated that around 1 in
7,000 adults have a mitochondrial disorder (Schaefer et al.
2008). Given this prevalence we might have expected to see
similar numbers of mitochondrial and PKU patients,
however various factors likely account for this discrepancy
– many patients will be seen by neurologists or other
specialty facilities (such as that at Newcastle upon Tyne in
the United Kingdom), as well as an incomplete diagnostic
rate in adults. As our study only included patients with
confirmed diagnoses, patients with “possible” or “probable”
mitochondrial disease (a group which is expected to be
significantly larger than the group of patients with a
confirmed molecular diagnosis of mitochondrial disease)
are not included in our data.
This data set is a “snapshot” of the patients that adult
metabolic physicians care for and is a useful tool for service
planning and building an awareness of the significant
burden of adult metabolic disease. It is not however a
comprehensive description of the epidemiology of these
patients. For example, the number of patients with MCAD
(48) is less than expected from prevalence data (1 in 4,900
(Sander et al. 2001) to 1 in 25,000 (Carpenter et al. 2001)).
Fifty percent of MCAD patients remain undetected in the
absence of screening (Wilcken et al. 2007), with the risk of
death in this group about 5–7% in the first 6 years and very
low thereafter (Wilcken 2010), although there are case
reports of previously undiagnosed adults dying (Lang
2009). Thus, a good proportion of unscreened MCAD
patients would be expected to reach adulthood undiag-
nosed. Some diagnosed MCAD patients would not be
transitioned to adult services as a result of being lost to
follow-up, and some may have been transitioned to
alternative services such as adult endocrinology. The
sample is also biased by the relative expertise and historical
interests of each centre; for example, many of the Pompe
patients come from the Rotterdam centre (106 of the 220
Table 5 Patient age group at diagnosis. French data submitted in
2014 was not included in this analysis
Age group at diagnosis Number of
patients





















patients), and other centres see fewer patients. Similarly,
120 of the 146 TMAU patients and 70 of the 87
hypophosphataemic rickets were seen at the Charles Dent
Metabolic Unit in London. Data was submitted from the
European, Canadian and Asia-Pacific centres only; hence,
our data may be different from patient populations seen at
centres in the United States and elsewhere.
Age Group at Diagnosis
Age group at diagnosis was available for approximately
2,000 patients and showed that more than 40% were
diagnosed in adulthood. This demonstrates the importance
of adult physicians being aware of metabolic diseases as a
diagnostic possibility. Mitochondrial disorders may present
with any combination of organ dysfunctions and at any
stage of life and may therefore be seen by nearly any type
of specialist physician, although neurologists are perhaps
the most likely to be involved given the strong representa-
tion of MELAS and CPEO patients in this group. Fabry
disease was also diagnosed almost exclusively in adulthood
(137 of 147 patients with age at diagnosis data), and given
its prevalence in hypertrophic cardiomyopathy, stroke and
end-stage renal failure cohorts (Rolfs et al. 2005; Gaspar
et al. 2010; Palecek et al. 2014), its importance to adult
physicians is noteworthy. It is, however, important to
realise that a diagnosis of Fabry disease can be difficult.
The availability of enzyme replacement therapy since 2,000
has triggered screening for this disorder, showing a steep
rise in prevalence of genetic and enzymatic diagnoses.
Traditionally, the prevalence of classical Fabry disease is
estimated to be around 1 in 40,000 (Desnick et al. 2007),
but this has changed to almost 1 in 3,000 in newborn
screening programmes (Spada et al. 2006). Since most
mutations in the GLA gene are private (Garman 2007), the
pathogenicity of newly identified variants is not always
clear. Many individuals picked up during screening do not
fulfil the classic criteria, and hence, there may be an
overestimation of cases (van der Tol et al. 2014).
Increasing Service Demands
Since these data was originally collected in 2011, each of
these clinical centres has experienced growth in patient
numbers (Table 1). The numbers listed in Table 1 include
only those patients with confirmed metabolic diagnoses.
Similar to paediatric services, many of the adult centres
follow a large number of patients who are either in the
process of undergoing diagnostic evaluation or in whom
the results of such evaluation are inconclusive (such as
patients with “possible” or “probable” mitochondrial
disease) and these patients need also to be considered in
the human resource requirements of adult clinics. The
proportion of patients requiring ongoing follow-up but in
whom a confirmed diagnosis had not yet been reached
varied from 15% to 50% in those centres where it was
known – these patients were not included in our analysis.
Increasing awareness of adult metabolic services is
responsible in part, as is ongoing transition of paediatric
patients.
We are aware that there is a sizable population of
paediatric metabolic patients who have been diagnosed by
tandem mass spectrometry newborn screening. In New
South Wales, Australia (population approximately 7.2
million), around twenty-five new patients with IEM are
diagnosed each year and the oldest of these patients is 15
years. This approaching cohort of transitioning paediatric
patients needs to be considered in future service planning.
There are an increasing number of previously rare
metabolic defects, like carnitine transporter deficiency,
being diagnosed in adult women when their infants have
positive results on expanded newborn screening panels
(Vijay et al. 2006). Although it is likely that many of these
women will be asymptomatic for life, there are case reports
suggesting that this disorder in adult women may be
associated with adverse health consequences such as
pregnancy loss (El-Hattab et al. 2010) and cardiomyopathy
(Lee et al. 2010). These patients will need to be followed to
clarify the long-term health consequences of these disor-
ders, and thus, the expanded newborn screening panels
adopted in many countries around the world have immedi-
ate resource implications for adult centres.
The majority of patients described in this cohort
potentially have some form of treatment available to them;
although in some localities ultra-expensive therapies like
enzyme replacement may be unavailable. Given that many
adult patients with IEM can be offered therapy, it would
seem sensible that treatment be guided by physicians with
expertise in these rare disorders. It should also not be
forgotten that amongst these diseases are those that, even
though extremely rare, can be well treated if diagnosed
early, such as tyrosinaemia type II (5 patients) and
cobalamin E deficiency (1 patient).
These data are also helpful in designing training
programmes for physicians who wish to care for adults
with inborn errors of metabolism. Training programmes
need to include exposure to acute metabolic medicine, such
as patients with decompensated urea cycle defects. How-
ever, such physicians also need expertise in adult neurol-
ogy, allowing for the evaluation of myopathies,
leukodystrophies, ataxic disorders and progressive cogni-
tive impairment, and experience in general internal medi-
cine to allow them to care for patients with lysosomal
storage diseases (who require a wide range of common
adult therapies such as ACE inhibitors, statins, antiplatelet
agents and therapies for osteoporosis).
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Conclusion
Our data show the wide range of paediatric and adult-onset
IEM seen in these clinical centres. The increase in adult
patient numbers is important to recognise, as it indicates an
increasing need for specialty services to be available to
these patients. Specialised knowledge of these disorders is
needed to provide optimal care, including up-to-date
monitoring and treatments and the ability to manage acute
decompensation. We consider that care for this growing
adult IEM patient population is important, as the vast
majority of these people participate fully in society and the
consequences of failed care can be catastrophic. This study
also demonstrates useful collaboration between members of
the SSIEM Adult Metabolic Physicians group and provides
information that will hopefully pave the way for future
cohort studies and clinical trials in adults with these rare
disorders.
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